Global Allergic Rhinitis Drugs Market 2018-2028 - Visiongain Report

News provided by

Aug 29, 2018, 09:15 ET

LONDON, August 29, 2018 /PRNewswire/ --

Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.3% in the first half of the forecast period. The market is estimated at $12.2bn in 2017 and $14.3bn in 2022.

(Photo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 256-page report you will receive 97 tables and 100 figures- all unavailable elsewhere.

The 256-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Allergic Rhinitis Drugs Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2028 for the following submarkets:
• Intranasal Antihistamines
• Intranasal Corticosteroids
• Oral Antihistamines
• Immunotherapy and Vaccines

• How will leading allergic rhinitis drugs perform to 2028 at world level? Our study forecasts individual revenues of these 27 products:
• Patanase
• Astepro
• Astelin
• Dymista
• Nasonex
• Avamys
• Veramyst
• Flixonase
• Rhinocort
• Omnaris
• Nasacort
• Beconase
• Qnasl
• Zetonna
• Allegra
• Zyrtec
• Claritin
• Xyzal
• Allelock
• Clarinex
• Ebastel
• Talion
• Staloral
• Alutard SQ
• Grazax
• Ragwitek
• Generic Azelastine

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• US
• EU5 - Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil
• Rest of the World

Each national market is further segmented by submarket.

• Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
• GlaxoSmithKline (GSK)
• Merck & Co
• Sanofi
• Johnson & Johnson
• ALK-Abello
• UCB
• Kyowo Hako Kirin
• Stallergenes Greer

• This report discusses the trends and development in the allergic rhinitis pipeline

• Our study discusses strengths, weaknesses, opportunities and threats as well as porter's five forces analysis of the global allergic rhinitis drugs market

Visiongain's study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Buy our report today Global Allergic Rhinitis Drugs Market 2018-2028: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website : https://www.visiongain.com/report/global-allergic-rhinitis-drugs-market-2018-2028/

ActoGeniX
Adamis Pharmaceuticals
ALK- Abelló
Allergy Medical UK
Allergy Therapeutics
Almirall
Altana Pharma (Nycomed)
Anergis
Apotex
AstraZeneca
Atopix Therapeutics
Barr Laboratories
Bausch & Lomb
Belcher Pharmaceuticals
Biotech Tools
Catalent Pharma Solutions
Celsus Therapeutics
Dainippon Sumitomo
DBV Technologies
Dr Reddy's Laboratories
Eddingpharm
Eleventa
Genzyme (Sanofi)
GlaxoSmithKline
Greer Laboratories
Hisamitsu Pharmaceutical Co
Hoechst AG
Human Genome Sciences
Intas Pharmaceuticals
Johnson & Johnson
Keldman Healthcare
Kyowa Hakko Kirin
Leti Pharma (Laboratorios Leti)
Lupin Pharmaceuticals
Meda Pharma
Medpointe Inc (Meda Pharma)
Merck & Co
Mitsubishi Tanabe Pharma
Mylan
Nippon Paper Group
Novartis
Omega Pharma
Perrigo
Pfizer
ProStrakan (Kyowa Hakko Kirin)
Reckitt Benckiser
Roxane Laboratories (Boehringer Ingelheim)
Sanofi
Schering-Plough (Merck)
Shionogi & Co Ltd
Stallergenes
Sun Pharmaceuticals
Sunovion Pharmaceuticals (Dainippon Sumitomo)
Takeda
Teva Pharmaceuticals
Trimel Pharmaceuticals
Ube Industries
UCB
ViiV Healthcare
Wockhardt
Ziarco Pharma